• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-3/A filed by EDAP TMS S.A.

    3/26/26 6:43:24 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $EDAP alert in real time by email
    S-3/A 1 s3a_032626.htm S-3/A

    As filed with the Securities and Exchange Commission on March 27, 2026

    Registration No. 333-294597

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-3

    (Amendment No. 1)

     

    REGISTRATION STATEMENT

    UNDER
    THE SECURITIES ACT OF 1933

    _________________________________

     

    EDAP TMS S.A.

    (Exact name of registrant as specified in its charter)

    _________________________________

     

    France   Not applicable
    (State or other jurisdiction
    of incorporation or organization)
      (I.R.S. Employer
    Identification No.)

     

    Parc d’Activités la Poudrette-Lamartine

    4/6, rue du Dauphiné

    69120 Vaulx-en-Velin, France

    +33(0) 4 72 15 31 50

    (Address, including zip code, and telephone number, including area code of registrant’s principal executive offices)

     

    EDAP Technomed Inc.

    5321 Industrial Oaks Blvd, Suite 110

    Austin, TX 78735

    U.S.A.

    Tel: + 1 512 832 7956

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Sanket Shah
    EDAP TMS S.A.
    4/6, rue du Dauphiné
    69120 Vaulx-en-Velin, France
    +33(0) 4 72 15 31 50
    ​ ​ ​ ​ Jeremy Cleveland
    JONES DAY
    1755 Embarcadero Road
    Palo Alto, California 94303
    (650) 739-3939

     

    From time to time after the effective date of this Registration Statement

    (Approximate date of commencement of proposed sale to the public)

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

     

     

     

     

     

     

    Explanatory Note

     

    EDAP TMS S.A. is hereby filing this Pre-Effective Amendment No. 1 to the Registration Statement on Form S-3 (Registration No. 333-294597), originally filed on March 25, 2026 (the “Registration Statement”), as an exhibit-only filing to file an opinion of Jones Day, filed herewith as Exhibit 5.1 (the “Opinion”). Accordingly, this Pre-Effective Amendment No. 1 consists only of the facing page, this explanatory note, Item 16 of Part II of the Registration Statement, the signature pages to the Registration Statement, and the Opinion filed herewith as Exhibit 5.1. The prospectus and the balance of Part II of the Registration Statement are unchanged and have been omitted.

     

     

    Item 16. Exhibits.

     

    A list of exhibits filed with this registration statement is set forth in the Exhibit Index, and such exhibits are incorporated into this Item 16 by reference.

     

     

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, EDAP TMS S.A. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Altos, United States of America, on March 27, 2026.

     

      EDAP TMS S.A.
       
       
       
      By: /s/ Ryan Rhodes
      Name:  Ryan Rhodes
      Title:  Chief Executive Officer and Director

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities indicated on March 27, 2026.

     

     

    Signature

     

    Title

     

    Date

             

    /s/ Ryan Rhodes

    Ryan Rhodes

      Chief Executive Officer and Director
    (Principal Executive Officer)
      March 27, 2026
             

    /s/ *

    Ken Mobeck

      Chief Financial Officer
    (Principal Financial Officer)
      March 27, 2026
             

    /s/ *

    François Dietsch

      Chief Accounting Officer
    (Principal Accounting Officer)
      March 27, 2026
             

    /s/ *

    Lance Willsey

      Chairman of the Board and Director   March 27, 2026
             

    /s/ *

    Fran Schulz

      Director   March 27, 2026
             

    /s/ *

    Josh Levine

      Director   March 27, 2026
             

    /s/ *

    David Horn

      Director   March 27, 2026

     

    * By: /s/ Ryan Rhodes  
      Ryan Rhodes, Attorney-in-Fact, March 27, 2026

     

     

     

     

     

     

     

    AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement on Form S-3 has been signed by the undersigned as the duly authorized representative in the United States of EDAP TMS S.A. in the City of Los Altos, United States of America, on March 27, 2026.

     

      EDAP TMS S.A.
       
       
       
      By: /s/ Ryan Rhodes
      Name:  Ryan Rhodes
      Title:  Chief Executive Officer and Director

     

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.

     

    Description

    1.1*   Form of Underwriting Agreement.
    3.1**   By-laws (statuts) of EDAP TMS S.A. (English translation) as amended as of December 18, 2025 (Incorporated herein by reference to Exhibit 3.1 of EDAP TMS S.A.’s Annual Report on Form 10-K for the year ended December 31, 2025 filed March 25, 2026, SEC File Number 000-29374).
    4.1**   Form of Amended and Restated Deposit Agreement between EDAP TMS S.A., The Bank of New York Mellon, as depositary and owners and beneficial owners of American Depositary Shares issued thereunder (incorporated herein by reference to Exhibit 1.2 to Form F-6 dated September 15, 2011, SEC File No. 333-176843).
    4.2**   Form of American Depositary Receipt (included in Exhibit 4.1).
    4.3*   Form of Warrant.
    5.1   Opinion of Jones Day, French counsel to the registrant.
    5.2**   Opinion of Jones Day, counsel to the registrant (incorporated herein by reference to Exhibit 5.2 to Form S-3 dated March 25, 2026, SEC File No. 333-294597).
    10.1**   Finance Contract, dated as of October 17, 2025, between the Company and the European Investment Bank (incorporated herein by reference to Exhibit 99.1 to Form 6-K dated October 20, 2025, SEC File No. 000-29374).
    10.2**   Warrant Agreement, dated as of October 17, 2025, between the Company and the European Investment Bank (incorporated herein by reference to Exhibit 99.2 to Form 6-K dated October 20, 2025, SEC File No. 000-29374).
    23.1**   Consent of KPMG S.A. (incorporated herein by reference to Exhibit 23.1 to Form S-3 dated March 25, 2026, SEC File No. 333-294597)
    23.2   Consent of Jones Day (included in Exhibits 5.1 and 5.2 (incorporated herein by reference to Exhibit 5.2 to Form S-3 dated March 25, 2026, SEC File No. 333-294597)).
    24.1**   Powers of Attorney (incorporated herein by reference to the signature pages to Form S-3 dated March 25, 2026, SEC File No. 333-294597).
    107**   Calculation of Filing Fee Table (incorporated herein by reference to Exhibit 107 to Form S-3 dated March 25, 2026, SEC File No. 333-294597)

    ________________

    *To be filed, if necessary, subsequent to the effectiveness of this Registration Statement by an amendment to this Registration Statement or as an exhibit to a report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and incorporated herein by reference.

     

    **Filed previously 

     

     

     

    Get the next $EDAP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EDAP

    DatePrice TargetRatingAnalyst
    5/15/2025Overweight → Neutral
    Piper Sandler
    4/4/2025$2.00Buy → Hold
    Jefferies
    11/1/2022$11.00Buy
    Jefferies
    11/19/2021$12.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EDAP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue

    EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of U.S. Focal One Procedures69% Full-Year YoY Growth in Focal One System Placements28% Q4 YoY Growth in U.S. Procedures, Marking the Second Consecutive Quarter of Double-Digit Procedure GrowthDemand for Focal One Systems Remains Strong with System Placements in Academic Cancer Centers, Community Hospitals, and Large Integrated Healthcare Networks Company Reiterates its Previously Issued 2026 Revenue Guidance; HIFU Revenue Expected to Grow Between 34% and 45% YoY AUSTIN, Texas, March 25, 2026 - E

    3/25/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference

    EDAP to Present at Oppenheimer 36th Annual Healthcare MedTech & Services Conference Company to Present and Host 1x1 Investor Meetings on Wednesday, March 18th, 2026 AUSTIN, Texas, March 10, 2026 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and, together with Ken Mobeck, Chief Financial Officer, will host 1x1 investor meetings at the upcoming Oppenheimer 36th Annual Healthcare MedTech & Services Conference. Date: Wednesday, March 18th Time: 12:00-12:30 PM ET Format: Virtual Presentation and 1x1 investor meetings Webcast:https://event.summitcast.com/vi

    3/10/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026

    EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026 Company to host conference call and webcast on Wednesday, March 25 at 8:30 a.m. EDT AUSTIN, Texas, March 4, 2026 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, before market open on Wednesday, March 25, 2026. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below f

    3/4/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Horn David R.

    3 - EDAP TMS SA (0001041934) (Issuer)

    2/13/26 5:59:52 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    New insider Annen Steven claimed ownership of 41,490 shares (SEC Form 3)

    3 - EDAP TMS SA (0001041934) (Issuer)

    1/14/26 4:05:55 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    New insider Rhodes Ryan claimed ownership of 301,149 shares (SEC Form 3)

    3 - EDAP TMS SA (0001041934) (Issuer)

    1/14/26 4:05:30 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    SEC Filings

    View All

    Amendment: SEC Form S-3/A filed by EDAP TMS S.A.

    S-3/A - EDAP TMS SA (0001041934) (Filer)

    3/26/26 6:43:24 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form S-3 filed by EDAP TMS S.A.

    S-3 - EDAP TMS SA (0001041934) (Filer)

    3/25/26 4:25:10 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-K filed by EDAP TMS S.A.

    10-K - EDAP TMS SA (0001041934) (Filer)

    3/25/26 4:15:58 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    EDAP TMS SA downgraded by Piper Sandler

    Piper Sandler downgraded EDAP TMS SA from Overweight to Neutral

    5/15/25 1:10:07 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP TMS SA downgraded by Jefferies with a new price target

    Jefferies downgraded EDAP TMS SA from Buy to Hold and set a new price target of $2.00

    4/4/25 8:36:35 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Jefferies initiated coverage on EDAP TMS SA with a new price target

    Jefferies initiated coverage of EDAP TMS SA with a rating of Buy and set a new price target of $11.00

    11/1/22 6:28:24 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    Leadership Updates

    Live Leadership Updates

    View All

    EDAP Announces Appointment of David Horn to Board of Directors

             EDAP Announces Appointment of David Horn to Board of Directors AUSTIN, Texas, February 12, 2026 – EDAP TMS S.A. (NASDAQ:EDAP) ("the Company" or "EDAP"), a global leader in therapeutic ultrasound technology, today announced the appointment of David Horn to its Board of Directors, effective February 11, 2026. The addition of Mr. Horn strengthens the Board with extensive experience both advising and leading companies through periods of strategic growth and transformation. Mr. Horn will serve as a member of the Company's Audit Committee and Nominations Committee. "We are pleased to welcome David to the EDAP Board," said Lance Willsey, Chairman of the Board of EDAP. "David brings dee

    2/12/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP Appoints Joshua H. Levine to Board of Directors

    PDF Version AUSTIN, Texas, January 10, 2025 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Joshua H. Levine to its Board of Directors.  "We are pleased to welcome Josh Levine to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. "Josh brings a wealth of executive experience and a track record of growing shareholder value by focusing on transformative, high growth business strategies within the medical technology sector. As EDAP continues to grow the market for its leading Focal One   robotic HIFU platform, Josh will help shape our strategic vision and ex

    1/10/25 7:00:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP Appoints Fran Schulz to Board of Directors

    PDF Version LYON, France, July 8, 2024 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company" or "EDAP"), the global leader in robotic energy-based therapies, today announced the appointment of Fran Schulz to its Board of Directors. "We are pleased to welcome Fran Schulz to our Board of Directors," said Marc Oczachowski, Chairman of the Board of EDAP TMS. "Fran brings a wealth of executive experience in the healthcare industry, and her expertise spans across a broad array of strategic finance and accounting functions. She also possesses an in-depth understanding of U.S. and international regulatory issues, which will further strengthen our Board's leadership as we continue to expand Focal One global

    7/8/24 7:00:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    Financials

    Live finance-specific insights

    View All

    EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue

    EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of U.S. Focal One Procedures69% Full-Year YoY Growth in Focal One System Placements28% Q4 YoY Growth in U.S. Procedures, Marking the Second Consecutive Quarter of Double-Digit Procedure GrowthDemand for Focal One Systems Remains Strong with System Placements in Academic Cancer Centers, Community Hospitals, and Large Integrated Healthcare Networks Company Reiterates its Previously Issued 2026 Revenue Guidance; HIFU Revenue Expected to Grow Between 34% and 45% YoY AUSTIN, Texas, March 25, 2026 - E

    3/25/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026

    EDAP to Announce Fourth Quarter and Full Year 2025 Financial Results on March 25, 2026 Company to host conference call and webcast on Wednesday, March 25 at 8:30 a.m. EDT AUSTIN, Texas, March 4, 2026 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full year ended December 31, 2025, before market open on Wednesday, March 25, 2026. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below f

    3/4/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP Reports Third Quarter 2025 Financial Results

    EDAP Reports Third Quarter 2025 Financial Results 49% YoY HIFU Revenue Growth, Driven by Increased Focal One® Sales and U.S. Procedure Volumes167% YoY Growth in Focal One System Placements15% YoY Growth in U.S. Focal One HIFU ProceduresCompany to Host Conference Call and Webcast on November 6 at 8:30 a.m. ET AUSTIN, Texas, November 6, 2025 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, reported today unaudited consolidated financial results for the third quarter of 2025. "Our record-breaking third-quarter revenue performance reflects the continued strong demand for our leading Focal One Robotic HIFU platform, with system placements increasing 167% year o

    11/6/25 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by EDAP TMS S.A.

    SC 13G/A - EDAP TMS SA (0001041934) (Subject)

    11/14/24 3:36:33 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by EDAP TMS S.A. (Amendment)

    SC 13G/A - EDAP TMS SA (0001041934) (Subject)

    2/2/24 9:41:45 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by EDAP TMS S.A. (Amendment)

    SC 13G/A - EDAP TMS SA (0001041934) (Subject)

    2/14/23 8:19:52 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care